Advertisement
News
Subscribe to MDT Magazine News

SABCS 2010: Interview with Ivis Febus-Sampayo

December 10, 2010 7:35 am | by AACR | Comments

Ms. Febus-Sampayo discusses the cultural challenges faced by Latina women when they receive a cancer diagnosis, shares advice about how clinicians can best serve the Latina women who have cancer, and the long-term goals of her organization.

TOPICS:

New Poll: Voters Want to Reduce Wasteful Spending in Medicaid Pharmacy

December 10, 2010 7:35 am | by Bio-Medicine.Org | Comments

WASHINGTON, Dec. 10, 2010 /PRNewswire-USNewswire/ -- Voters would rather reduce Medicaid spending by better managing pharmacy benefits rather than cutting benefits for patients or payments to doctors and hospitals, according to a new poll commissioned by the Pharmaceutical Care Management...

TOPICS:

Advanced BioHealing Appoints Kevin C. O'Boyle as Chief Financial Officer

December 10, 2010 7:35 am | by Bio-Medicine.Org | Comments

WESTPORT, Conn., Dec. 10, 2010 /- Advanced BioHealing, Inc. (ABH), a leader in commercializing cell-based therapies and delivering on the promise of regenerative medicine , today announced the appointment of Kevin C. O'Boyle, as Senior Vice President and Chief Financial Officer. (Photo:...

TOPICS:
Advertisement

Hanger Orthopedic Group, Inc. Announces Pricing of Underwritten Public Offering by Shareholder

December 10, 2010 7:34 am | by Bio-Medicine.Org | Comments

AUSTIN, Texas, Dec. 10, 2010 /- Hanger Orthopedic Group, Inc. (NYSE: HGR ) announced today the pricing of the previously announced public offering of 2,000,000 shares of its common stock by Ares Corporate Opportunities Fund, L.P. at a public offering price of $20.00 per share.  The...

TOPICS:

SABCS 2010: Interview with Carlos L. Arteaga, M.D.

December 10, 2010 7:34 am | by AACR | Comments

Dr. Arteaga discusses targeted drugs for breast cancer, endocrine resistance, clinical trial enrollment criteria and his reactions to some of the important presentations at this year's symposium.

TOPICS:

SABCS 2010: Interview with Chi Van Dang, M.D., Ph.D.

December 10, 2010 7:34 am | by AACR | Comments

Dr. Dang discusses the major points of his plenary session, “Oncogenic Reprogramming of Metabolism and Therapy,” including how oncogenic alterations in cancers lead to altered tumor metabolism, and the function of the c-myc oncoprotein, which has emerged as a central oncogenic switch in...

TOPICS:

SABCS 2010: Interview with Stacy L. Moulder, M.D.

December 10, 2010 7:33 am | by AACR | Comments

Dr. Moulder talks about her research on PARP inhibitors for hard-to-treat breast cancers, such as triple-negative breast cancer, and the collaborative team that continues this line of research.

TOPICS:

SABCS 2010: Interview with George W. Sledge Jr., M.D.

December 10, 2010 7:33 am | by AACR | Comments

Dr. Sledge talks about the results of the first large nationwide study on the use of Taxol for advanced breast cancer, his perspective on new therapies for breast cancer, and his goals as president of the American Society of Clinical Oncology.

TOPICS:
Advertisement

BG Medicine plans IPO of up to $71.2M

December 10, 2010 6:33 am | by Mass High Tech: The Journal of New England Technology | Comments

BG Medicine Inc., the Waltham-based developer of biomarker-based diagnostic tools, is expected to announce an initial public offering of up to $71.2 million, according to a regulatory filing. The 4.7 million shares, planned for between $13 and $15, is expected to be priced next week, a...

2010 SABCS: AZURE Trial Teleconference

December 10, 2010 6:32 am | by AACR | Comments

Robert E. Coleman, M.D., professor and honorary consultant medical oncologist at the Cancer Research Center, Academic Unit Medical of Clinical Oncology at Weston Park Hospital in Sheffield, England, presents the results of the AZURE (Adjuvant Zoledronic Acid to Reduce Recurrence) trial at...

TOPICS:

Boston Micromachines, Bridger Photonics sign consulting deal

December 10, 2010 5:33 am | by I-Micronews | Comments

Boston Micromachines Corp. (BMC) announced Monday that it has signed a consulting agreement with Bridger Photonics Inc. to quantitatively assess a new MEMS membrane deformable mirror design using BMC?s facilities.

Mylan Receives Approval for Generic Version of Adalat® CC Tablets

December 10, 2010 5:32 am | by Bio-Medicine.Org | Comments

PITTSBURGH, Dec. 10, 2010 /- Mylan Inc. (Nasdaq: MYL ) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Nifedipine Extended-release Tablets USP,...

TOPICS:

Tomophase OCTIS(TM) Receives FDA 510(K) Clearance to Market

December 10, 2010 5:31 am | by Bio-Medicine.Org | Comments

BURLINGTON, Mass., Dec. 10, 2010 /- Tomophase Corporation, developer of the non-invasive Optical Coherence Tomography Imaging System (OCTIS™) and other devices, announced today that it has received FDA 510(k) clearance to market OCTIS. Tomophase is a leader in the development of OCT...

TOPICS:

Combination Therapy Reduced HER2-positive Breast Cancers

December 10, 2010 4:35 am | by AACR | Comments

SAN ANTONIO - A combination of lapatinib, trastuzumab and paclitaxel significantly improved tumor response rates than either agent alone among patients with HER2-positive breast cancers, according to data presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held...

TOPICS:

Pertuzumab and Trastuzumab Combination Improved Efficacy for Women With HER2-positive Breast Cancer

December 10, 2010 4:34 am | by AACR | Comments

SAN ANTONIO - The combination of pertuzumab and trastuzumab had superior antitumor activity in women with early HER2-positive breast cancer, according to Phase II study results of the NeoSphere neoadjuvant trial.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading